Analysts focus on three programs in big year for Bristol Myersnews2026-04-30T15:33:19+00:00April 30th, 2026|Endpoints News|
XTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue risenews2026-04-30T15:13:09+00:00April 30th, 2026|Endpoints News|
What we heard at a health tech conference in Bostonnews2026-04-30T14:29:09+00:00April 30th, 2026|Endpoints News|
CVS’ healthcare delivery chief eyes potential in clinical AInews2026-04-30T13:00:27+00:00April 30th, 2026|Endpoints News|
Updated: Early sales of Lilly’s obesity pill appear to trail Novo’snews2026-04-30T11:19:05+00:00April 30th, 2026|Endpoints News|
The R&D 15: How pharma’s top companies spent, won and lost on drug researchnews2026-04-30T11:15:51+00:00April 30th, 2026|Endpoints News|
Novartis unveils North Carolina factory as final new build in $23B US expansionnews2026-04-30T11:00:00+00:00April 30th, 2026|Endpoints News|
AbbVie faces questions about Skyrizi competition from J&Jnews2026-04-29T18:52:56+00:00April 29th, 2026|Endpoints News|
FDA, AstraZeneca prep for oncology adcommnews2026-04-29T18:32:20+00:00April 29th, 2026|Endpoints News|
Bristol Myers reaches a crossroads as a make-or-break year takes shapenews2026-04-29T15:33:16+00:00April 29th, 2026|Endpoints News|
